To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
Calando Patent Issued for Active Ingredient of Lead siRNA Drug Candidate, CALAA-01
Calando Pharmaceuticals, Inc. has the issuance of U.S. Patent No. 7,427,605, entitled, “Inhibitors of ribonucleotide reductase subunit 2 and uses thereof.”
The patent contains claims directed to inhibitory nucleic acid sequences targeting the Ribonucleotide Reductase Subunit 2 (R2) gene, as well as pharmaceutical compositions and methods for inhibiting tumor growth utilizing the sequences.
R2 is the gene targeted by Calando’s lead siRNA-containing nanoparticle therapeutic, CALAA-01, which is currently in a Phase I clinical trial for patients with non-resectable or metastatic solid tumors. CALAA-01 is the only RNAi therapeutic for cancer to have reached the clinic.
“The issuance of this patent is an important milestone for Calando,” said Dr. Jeremy Heidel, Ph.D., Calando’s Chief Scientific Officer for Nucleic Acid Delivery. “It provides a significant addition to the strong patent portfolio that Calando maintains for its CALAA-01 product.”
Add Technology Networks as a preferred Google source to see more of our trusted coverage.
